Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat Parkinson Disease
Shots:
- The P-ll RESTORE-1 study involves assessing NBIb-1817(VY-AADC) for the treatment of Parkinson's disease. Neurocrine & Voyager will closely work with FDA & DCMB to determine the next clinical trial for RESTORE-1
- DSMB request a clinical hold- follows the IND Safety Report submit by Neurocrine Biosciences related to the observation of MRI abnormalities in some RESTORE-1 study participants and requested additional patient-level data from the trial and plans to review data in early 2021
- NBIb-1817 is an investigational recombinant AAV serotype 2 vectors encoding the gene for human AADC help to produce AADC enzyme in brain cells & convert levodopa to dopamine
Ref: GlobeNewswire | Image: PR Newswire
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
